BSE:530233

Stock Analysis Report

Executive Summary

Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generics in India.

Snowflake

Fundamentals

Excellent balance sheet with solid track record.

Share Price & News

How has Auro Laboratories's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.5%

530233

-2.0%

IN Pharmaceuticals

0.5%

IN Market


1 Year Return

-28.6%

530233

-20.5%

IN Pharmaceuticals

0.9%

IN Market

Return vs Industry: 530233 underperformed the Indian Pharmaceuticals industry which returned -20.5% over the past year.

Return vs Market: 530233 underperformed the Indian Market which returned 0.9% over the past year.


Share holder returns

530233IndustryMarket
7 Day-4.5%-2.0%0.5%
30 Day3.5%-7.9%1.0%
90 Day-4.6%-7.3%-3.2%
1 Year-28.6%-28.6%-19.7%-20.5%2.8%0.9%
3 Year30.4%30.4%-27.8%-29.3%20.3%14.3%
5 Year633.3%633.3%-11.5%-14.1%43.1%29.8%

Price Volatility Vs. Market

How volatile is Auro Laboratories's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Auro Laboratories undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Undervalued: 530233 (₹52.8) is trading below our estimate of fair value (₹133.3)

Significantly Undervalued: 530233 is trading below fair value by more than 20%.


Price Based on Earnings

PE vs Industry: 530233 is good value based on its PE Ratio (6.8x) compared to the Pharmaceuticals industry average (15.7x).

PE vs Market: 530233 is good value based on its PE Ratio (6.8x) compared to the Indian market (13.1x).


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate 530233's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: 530233 is overvalued based on its PB Ratio (1.9x) compared to the IN Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is Auro Laboratories expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

-0.08%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: 530233's earnings are forecast to decline over the next 3 years (-0.08% per year).

Earnings vs Market: 530233's earnings are forecast to decline over the next 3 years (-0.08% per year).

High Growth Earnings: 530233's earnings are forecast to decline over the next 3 years.

Revenue vs Market: Insufficient data to determine if 530233's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if 530233's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if 530233's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Auro Laboratories performed over the past 5 years?

44.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 530233's earnings have grown significantly by 44.6% per year over the past 5 years.

Accelerating Growth: 530233's earnings growth over the past year (30.8%) is below its 5-year average (44.6% per year).

Earnings vs Industry: 530233 earnings growth over the past year (30.8%) exceeded the Pharmaceuticals industry 16.4%.


Return on Equity

High ROE: 530233's Return on Equity (28%) is considered high.


Return on Assets

ROA vs Industry: 530233 has a higher Return on Assets than the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: 530233 has significantly improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is Auro Laboratories's financial position?


Financial Position Analysis

Short Term Liabilities: 530233's short term assets (₹187.1M) exceeds its short term liabilities (₹64.6M)

Long Term Liabilities: 530233's short term assets (187.1M) exceeds its long term liabilities (95.9M)


Debt to Equity History and Analysis

Debt Level: 530233's debt to equity ratio (46.5%) is considered high

Reducing Debt: 530233's debt to equity ratio has reduced from 214.6% to 46.5% over the past 5 years.

Debt Coverage: 530233's debt is well covered by operating cash flow (84.9%).

Interest Coverage: 530233's interest payments on its debt are well covered by EBIT (9.6x coverage).


Balance Sheet

Inventory Level: 530233 has a high level of physical assets or inventory.

Debt Coverage by Assets: 530233's debt is covered by short term assets (assets are 2.312060x debt).


Next Steps

Dividend

What is Auro Laboratories's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%0.6%markettop25%2.5%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate 530233's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 530233's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if 530233's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 530233's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 530233's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

What is the CEO of Auro Laboratories's salary, the management and board of directors tenure and is there insider trading?

₹6m

CEO Compensation


CEO

Sharat Deorah (69yo)

0yrs

Tenure

₹6,000,000

Compensation

Mr. Sharat Sahadeolal Deorah, B.Com. serves as the Managing Director and Chairman of the Board at Auro Laboratories Limited. 


CEO Compensation Analysis

Compensation vs. Market: Sharat's total compensation ($USD84.59K) is about average for companies of similar size in the Indian market ($USD25.38K).

Compensation vs Earnings: Sharat's compensation has increased by more than 20% in the past year.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Sharat Deorah (69yo)

    Chairman & MD

    • Tenure: 0yrs
    • Compensation: ₹6.00m
  • Siddhartha Deorah (41yo)

    Whole Time Director

    • Tenure: 0yrs
    • Compensation: ₹6.00m
  • Amit Shah

    Chief Financial Officer

    • Tenure: 0yrs
    • Compensation: ₹1.04m
  • Shanu Nag

    Company Secretary

    • Tenure: 0yrs
    • Compensation: ₹180.10k

Board Members

  • Sharat Deorah (69yo)

    Chairman & MD

    • Tenure: 0yrs
    • Compensation: ₹6.00m
  • Govardhan Agarwal (70yo)

    Non-Executive Independent Director

    • Tenure: 0yrs
    • Compensation: ₹12.50k
  • Siddhartha Deorah (41yo)

    Whole Time Director

    • Tenure: 0yrs
    • Compensation: ₹6.00m
  • Kailash Bubna (65yo)

    Non-Executive Independent Director

    • Tenure: 10.3yrs
    • Compensation: ₹12.50k
  • Kavita Sharma

    Woman Director

    • Tenure: 5.6yrs
    • Compensation: ₹12.50k

Company Information

Auro Laboratories Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Auro Laboratories Limited
  • Ticker: 530233
  • Exchange: BSE
  • Founded: 1989
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹330.323m
  • Shares outstanding: 6.23m
  • Website: https://www.aurolabs.com

Number of Employees


Location

  • Auro Laboratories Limited
  • 314, T.V. Industrial Estate
  • 3rd Floor
  • Mumbai
  • Maharashtra
  • 400030
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
530233BSE (Mumbai Stock Exchange)YesEquity SharesININROct 2004

Biography

Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generics in India. It offers APIs for various drugs, such as antihistamine, muscle relaxant, di ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 12:31
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)